Paper Details

  1. Home
  2. Paper Details

Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.

Author: BaiJiaojiao, BaiJie, HaoXing, WangYingshao, XingWen, YuanJiajia, ZhouYuan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explores the synergistic effects of combining ruxolitinib, a JAK2 inhibitor, with vorinostat, a histone deacetylase inhibitor, in treating Philadelphia-negative myeloproliferative neoplasms (MPNs). The combination showed promising results in preclinical studies, suggesting it could be a potential dual-target therapy for MPNs.
Paper Details　
Original Abstract of the Article :
The majority of patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) harbor a gain of function mutation V617F in Janus kinase (JAK) 2. Although JAK2 inhibitors such as ruxolitinib have been shown to be clinically efficacious, the hematological toxicity and eventual drug resistance...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10637-019-00794-4

データ提供：米国国立医学図書館（NLM）

Combating Myeloproliferative Neoplasms: A Synergistic Approach

This research explores a novel combination therapy for myeloproliferative neoplasms (MPNs), targeting both the JAK/STAT signaling pathway and histone deacetylase. The study investigated the synergistic effects of combining ruxolitinib, a JAK inhibitor, with vorinostat, a histone deacetylase inhibitor. The researchers tested this combination in cell lines harboring the JAK2V617F mutation, a common genetic alteration in MPNs. Their findings suggest that this dual-target therapy could offer a potent and effective approach to combating MPNs.

Ruxolitinib and Vorinostat: A Powerful Combination

The study revealed that ruxolitinib and vorinostat synergistically induced apoptosis, cell cycle arrest, and inhibition of colony formation in MPN cells. This combination effectively targeted the JAK/STAT and AKT signaling pathways, disrupting key molecular mechanisms driving MPN progression. The researchers also observed significant inhibition of colony formation from bone marrow cells of patients with MPN, highlighting the potential of this combination therapy in clinical settings.

Navigating the Complexities of MPNs

This research underscores the importance of developing innovative therapeutic strategies for MPNs, a group of hematological malignancies often characterized by complex genetic alterations. The study’s findings on the synergistic effects of ruxolitinib and vorinostat provide a valuable insight into the potential for dual-target therapies, paving the way for future research and clinical applications. It’s like finding a double-headed camel to navigate the challenging desert of MPNs.

Dr. Camel's Conclusion

This study offers a promising glimpse into the future of MPN treatment. The findings suggest that combining ruxolitinib and vorinostat could be a powerful approach to combatting these complex hematologic malignancies. It's like finding a hidden oasis of hope in the desert of MPN challenges.
Date :
  1. Date Completed 2021-06-01
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31227936

DOI: Digital Object Identifier

10.1007/s10637-019-00794-4

Related Literature

Article Analysis
・Effects of vorinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.